CX3CL1 and Alzheimer disease: Our findings revealed significantly decreased levels of NPTXR as well as increased concentrations of CXCL12, CX3CL1, and YKL-40, and biomarkers of synaptic damage-Ng in MCI and AD patients as compared to controls (Table 2, Figure 1).